Next-Generation Sequencing (NGS) of TP53, ASXL1, RUNX1, EZH2, and ETV6 in Myelodysplastic Syndrome (MDS) with Isolated Del(5q): Correlation with Clinical and Morphologic Features

被引：0
|
作者：
Kwok, B. [1 ]
Reddy, P. [1 ]
Yung, A. [1 ]
Flamholz, R. [1 ]
Mohrmann, R. [1 ]
Dabbas, B. [1 ]
Xu, Y. [1 ]
机构：
[1] Genoptix Med Lab, Carlsbad, CA USA
来源：
MODERN PATHOLOGY | 2014年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1470
引用
收藏
页码：357A / 357A
页数：1
相关论文
共 10 条
  • [1] Next-Generation Sequencing (NGS) of TP53, ASXL1, RUNX1, EZH2, and ETV6 in Myelodysplastic Syndrome (MDS) with Isolated Del(5q): Correlation with Clinical and Morphologic Features
    Kwok, B.
    Reddy, P.
    Yung, A.
    Flamholz, R.
    Mohrmann, R.
    Dabbas, B.
    Xu, Y.
    LABORATORY INVESTIGATION, 2014, 94 : 357A - 357A
  • [2] Practical Application of Next-Generation DNA Sequencing in Detection of ASXL1, RUNX1, EZH2, ETV6, and TP53 Mutations in Patients wtih Myelodysplastic Syndromes
    Nguyen, J.
    Moscinski, L.
    Zhang, L.
    LABORATORY INVESTIGATION, 2014, 94 : 365A - 365A
  • [3] Practical Application of Next-Generation DNA Sequencing in Detection of ASXL1, RUNX1, EZH2, ETV6, and TP53 Mutations in Patients wtih Myelodysplastic Syndromes
    Nguyen, J.
    Moscinski, L.
    Zhang, L.
    MODERN PATHOLOGY, 2014, 27 : 365A - 365A
  • [4] Next-Generation Sequencing Of ASXL1, TP53, RUNX1, EZH2, and ETV6 Identifies a Significant Proportion Of Lower-Risk Myelodysplastic Syndromes With Poor Prognostic Indicators
    Kwok, Brian
    Mohrmann, Renee
    Janatpour, Kim
    Xu, Yin
    McGinniss, Matthew
    Yung, Aine
    Drum, Hong
    Lin, Keming
    Kines, Julie
    Tasmin, Jeffrey
    Dabbas, Bashar
    BLOOD, 2013, 122 (21)
  • [5] Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)
    Lode, Laurence
    Menard, Audrey
    Loirat, Marion
    Halliez, Maxime
    Richebourg, Steven
    Talmant, Pascaline
    Godon, Catherine
    Theisen, Olivier
    Le Bris, Yannick
    Girard, Cecile
    Blin, Nicolas
    Luycx, Odile
    Sadot-Lebouvier, Sophie
    Morineau, Nadine
    Godmer, Pascal
    Subiger, Francois
    Villemagne, Bruno
    Eveillard, Marion
    Wuilleme, Soraya
    Kohlmann, Alexander
    Moreau, Philippe
    Delaunay, Jacques
    Bene, Marie C.
    BLOOD, 2013, 122 (21)
  • [6] ABT-199 EFFECTIVELY INDUCES APOPTOSIS IN HIGH-RISK MDS PROGENITOR CELLS IRRESPECTIVE OF PROGNOSTICALLY ADVERSE MUTATIONS OF TP53, EZH2, RUNX1, AND ASXL1
    Kauschinger, J.
    Jilg, S.
    Reidel, V.
    Mueller-Thomas, C.
    Hoeckendorf, U.
    Schauwecker, J.
    Goetze, K.
    Peschel, C.
    Jost, P.
    HAEMATOLOGICA, 2016, 101 : 492 - 493
  • [7] BCL-2 INHIBITION BY ABT-199 POTENTLY INDUCES CELL DEATH IN MDS PROGENITORS DESPITE HIGH-RISK MUTATIONS IN ASXL1, RUNX1, TP53 OR EZH2
    Jilg, S.
    Reidel, V.
    Kauschinger, J.
    Mueller-Thomas, C.
    Hauch, R.
    Schauwecker, J.
    Burkhard, S.
    Hoeckendorf, U.
    Peschel, C.
    Kern, W.
    Haferlach, T.
    Slotta-Huspenina, J.
    Goetze, K. S.
    Jost, P. J.
    LEUKEMIA RESEARCH, 2017, 55 : S156 - S156
  • [8] TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial
    Mossner, Maximilian
    Jann, Johann-Christoph
    Lauinger-Loersch, Evi
    Nowak, Daniel
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Goetze, Katharina S.
    Letsch, Anne
    Haase, Detlef
    Shirneshan, Katayoon
    Schlenk, Richard F.
    Kohlmann, Alexander
    Haferlach, Torsten
    Bug, Gesine
    Luebbert, Michael
    Ganser, Arnold
    Oblaender, Julia
    Fey, Stephanie
    Hofmann, Wolf-Karsten
    Germing, Ulrich
    Nolte, Florian
    BLOOD, 2013, 122 (21)
  • [9] Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
    Ohgami, Robert S.
    Ma, Lisa
    Merker, Jason D.
    Gotlib, Jason R.
    Schrijver, Iris
    Zehnder, James L.
    Arber, Daniel A.
    MODERN PATHOLOGY, 2015, 28 (05) : 706 - 714
  • [10] 454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial
    Mossner, M.
    Nowak, D.
    Platzbecker, U.
    Giagounidis, A.
    Goetze, K.
    Letsch, A.
    Haase, D.
    Shimeshan, K.
    Schlenk, R.
    Kohlmann, A.
    Haferlach, T.
    Bug, G.
    Luebbert, M.
    Ganser, A.
    Jann, J-C
    Oblaender, J.
    Fey, S.
    Hofmann, W-K
    Germing, U.
    Nolte, F.
    ONKOLOGIE, 2013, 36 : 126 - 126
1